Cancer immunotherapy

#Cancer immunotherapy #Cancer research #Clinical trials #Immuno-oncology #Immunology / Virology & Vaccines #Tumour biology

Collaboration to develop a novel cancer immunotherapy  

Terumo Blood and Cell Technologies and PhotonPharma have established a memorandum of understanding (MOU) for collaboration to develop Innocell, a novel tumour specific immunotherapy (a therapeutic vaccine)… Read More

#Cancer Research #News

#Biotherapeutics #Cancer immunotherapy #Cancer research #Chemotherapy #Oncology #Therapeutics

Study could combat aggressive chemotherapy resistant TNBC

A Mount Sinai study titled Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease describes how a novel therapeutic (108600) combats aggressive chemotherapy-resistant triple-negative breast cancer (TBNC). 108600 targets and inhibits breast cancer stem cells, a subpopulation of cells found within patient triple negative… Read More

#Editor's Choice #News

#Cancer immunotherapy #Cancer research #Immuno-oncology #Immunology #Tumour biology

Cancer project enters Immuno-oncology Alliance

In the UK, researchers Professor Andrew Beggs and Professor Gary Middleton from the Institute of Immunology and Immunotherapy and the Institute of Cancer and Genomic Sciences have partnered with Cancer Research UK in a target identification project for the Immuno-oncology Alliance, which translates discovery science into new therapeutics for cancer… Read More

#Cancer Research #News

#Cancer immunotherapy #Cancer research #Drug development

Are women less susceptible to some skin cancers?

Women may have a stronger immune response to a common form of skin cancer than men, according to early research on mice and human cells. Led by University of Manchester scientists at the Cancer Research UK Manchester Institute, the team publish their findings in Clinical Cancer Research. Men have more… Read More

#Cancer Research #News #Trending News

#Cancer immunotherapy #Cancer research #Research

First large study of immunotherapy in black cancer patients

A new collaboration between Roswell Park Comprehensive Cancer Center and University of Rochester’s Wilmot Cancer Institute will help oncologists learn whether black and white cancer patients respond differently to immunotherapy treatment and seeks to improve the safety and effectiveness of these newer drugs in diverse populations. Funded by a two-year,… Read More

#Cancer Research #News

#Biologics / Biotechnology #Biotherapeutics #Cancer immunotherapy #Drug discovery

Bicara Therapeutics launches biologics for cancer immunotherapy

Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to spur a potent and durable immune response in the tumour microenvironment, launched with a US$40 million investment from Biocon. The financing will be used to advance a pipeline of first-in-class bifunctional antibodies developed by a global team, including a… Read More

#Cancer Research #News

#Biologics / Biotechnology #Cancer immunotherapy #Cancer research #Drug development

Pathios Therapeutics boosted with Innovate UK funding

Pathios, a biotech company focused on the development of first-in-class therapies for cancer, announced that it has been awarded £350K in the form of a Smart Grant from Innovate UK. The UK government innovation agency’s money will accelerate Pathios’ cancer immunotherapy programme which targets the innate immune checkpoint, GPR65. Pathios… Read More

#Cancer Research #News

#Biologics #Cancer immunotherapy #Oncology

Samsung Biologics obtains cancer immunotherapy IND approval from FDA

Samsung Biologics has obtained Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy. In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal… Read More

#Cancer Research #News